Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2Recruiting 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 4997Neoplasms 4192Prostatic Neoplasms 2426Carcinoma, Non-Small-Cell Lung 2261Colorectal Neoplasms 2050Lung Neoplasms 1703Multiple Myeloma 1454Lymphoma 1403Leukemia, Myeloid, Acute 1379Neoplasm Metastasis 1372Melanoma 1269Pancreatic Neoplasms 1200Leukemia 1194Ovarian Neoplasms 1190Lymphoma, Non-Hodgkin 1128Precursor Cell Lymphoblastic Leukemia-Lymphoma 1088Head and Neck Neoplasms 1055Leukemia, Lymphocytic, Chronic, B-Cell 994Lymphoma, Follicular 896Colonic Neoplasms 893Brain Neoplasms 875Stomach Neoplasms 854Recurrence 848Carcinoma, Hepatocellular 845Glioblastoma 837Lymphoma, Large B-Cell, Diffuse 770Rectal Neoplasms 758Uterine Cervical Neoplasms 725Carcinoma, Renal Cell 704Hodgkin Disease 696

Interventions

Docetaxel 2Androgen Antagonists 2darolutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Interventional × Metastatic Hormone-sensitive Prostate Cancer × Clear all
NCT00309985 2025-12-11

CHAARTED

Eastern Cooperative Oncology Group

Phase 3 Completed
790 enrolled 11 charts
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT02799602 2025-12-04

ARASENS

Bayer

Phase 3 Completed
1,306 enrolled 25 charts 2 FDA
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡